Payment overview · 2025
General Payments
$299.51
18 reported records · 10 companies
Healthcare provider profile · identity verified
Carol B Peddicord, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, KY · NPI 1912990607
Verified facts
What the public records show
CMS Open Payments records show Carol B Peddicord, MD received $299.51 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta, Trintellix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.92 | 22.3% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.65 | 18.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.16 | 17.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.34 | 10.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.40 | 6.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.84 | 5.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.82 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.14 | 5.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $13.63 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.61 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.51 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.65 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.96 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 297 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 132 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1098 | 110 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1025 | 178 |
| Levothyroxine Sodium | Levothyroxine Sodium | 953 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 951 | 157 |
| Losartan Potassium | Losartan Potassium | 753 | 123 |
| Lisinopril | Lisinopril | 717 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 642 | 120 |
| Gabapentin | Gabapentin | 613 | 75 |
| Furosemide | Furosemide | 595 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 549 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 473 | 83 |
| Potassium Chloride | Potassium Chloride | 419 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 366 | 66 |
| Alprazolam | Alprazolam | 350 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 345 | 54 |
| Lorazepam | Lorazepam | 344 | 54 |
| Omeprazole | Omeprazole | 337 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 336 | 50 |
| Metformin Hcl | Metformin Hcl | 314 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 309 | 78 |
| Carvedilol | Carvedilol | 298 | 45 |
| Eliquis | Apixaban | 297 | 47 |
| Meloxicam | Meloxicam | 288 | 49 |
| Atenolol | Atenolol | 281 | 45 |
| Simvastatin | Simvastatin | 277 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 245 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 41 |
| Famotidine | Famotidine | 229 | 43 |
| Ibuprofen | Ibuprofen | 224 | 41 |
| Montelukast Sodium | Montelukast Sodium | 203 | 38 |
| Trazodone Hcl | Trazodone Hcl | 203 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 189 | 25 |
| Glipizide | Glipizide | 188 | 26 |
| Tramadol Hcl | Tramadol Hcl | 184 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 180 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 179 | 23 |
| Topiramate | Topiramate | 174 | 35 |
| Prednisone | Prednisone | 166 | 36 |
| Ondansetron Hcl | Ondansetron Hcl | 165 | 45 |
| Jardiance | Empagliflozin | 163 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 51 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 153 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 153 | 31 |
| Januvia | Sitagliptin Phosphate | 149 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 142 | 21 |
| Sertraline Hcl | Sertraline Hcl | 140 | 23 |
| Cefuroxime | Cefuroxime Axetil | 139 | 80 |
| Ondansetron Odt | Ondansetron | 138 | 36 |
| Allopurinol | Allopurinol | 137 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 18 |
| Ozempic | Semaglutide | 132 | 32 |
| Azithromycin | Azithromycin | 130 | 83 |
| Memantine Hcl | Memantine Hcl | 129 | 21 |
| Mounjaro | Tirzepatide | 125 | 22 |
| Fluconazole | Fluconazole | 119 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 20 |
| Spironolactone | Spironolactone | 118 | 30 |
| Warfarin Sodium | Warfarin Sodium | 118 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 18 |
| Amoxicillin | Amoxicillin | 102 | 52 |
| Clonidine Hcl | Clonidine Hcl | 98 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 95 | 16 |
| Bupropion Hcl | Bupropion Hcl | 93 | 19 |
| Levofloxacin | Levofloxacin | 93 | 60 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 22 |
| Meclizine Hcl | Meclizine Hcl | 90 | 28 |
| Nystatin | Nystatin | 90 | 45 |
| Promethazine Hcl | Promethazine Hcl | 90 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 17 |
| Diazepam | Diazepam | 87 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 53 |
| Clonazepam | Clonazepam | 84 | 11 |
| Farxiga | Dapagliflozin Propanediol | 84 | 17 |
| Mirtazapine | Mirtazapine | 80 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | suppressed |
| Synthroid | Levothyroxine Sodium | 68 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 67 | 26 |
| Donepezil Hcl | Donepezil Hcl | 66 | 11 |
| Divalproex Sodium | Divalproex Sodium | 65 | suppressed |
| Lansoprazole | Lansoprazole | 65 | suppressed |
| Pregabalin | Pregabalin | 64 | 14 |
| Glipizide Er | Glipizide | 61 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 59 | 20 |
| Entresto | Sacubitril/Valsartan | 57 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 11 |
| Methocarbamol | Methocarbamol | 56 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 36 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 54 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 54 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 54 | 11 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 53 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 50 | suppressed |
| Temazepam | Temazepam | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 32 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Sucralfate | Sucralfate | 47 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 46 | suppressed |
| Verapamil Er | Verapamil Hcl | 46 | suppressed |
| Metolazone | Metolazone | 45 | suppressed |
| Nitroglycerin | Nitroglycerin | 45 | 23 |
| Baclofen | Baclofen | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Naproxen | Naproxen | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 42 | suppressed |
| Lamotrigine | Lamotrigine | 42 | suppressed |
| Celecoxib | Celecoxib | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | suppressed |
| Colchicine | Colchicine | 38 | 17 |
| Labetalol Hcl | Labetalol Hcl | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 19 |
| Brilinta | Ticagrelor | 37 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Estradiol | Estradiol | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 19 |
| Gemfibrozil | Gemfibrozil | 32 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 31 | 14 |
| Linzess | Linaclotide | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Cilostazol | Cilostazol | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Ibu | Ibuprofen | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 28 | 24 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Xifaxan | Rifaximin | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 20 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Dofetilide | Dofetilide | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 14 |
| Mupirocin | Mupirocin | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Propylthiouracil | Propylthiouracil | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 15 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.51 · 18 records | Novo Nordisk Inc | ACCRUFER, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, NURTEC ODT, Ozempic, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error